MA-BOARD-INTERNATIONAL
2.11.2020 17:45:10 CET | Business Wire | Press release
Global decision-making platform vendor Board International has come out on top in Dresner Advisory Services’ Wisdom of Crowds® Sales Performance Management Market Study 2020 .
"Congratulations to Board ranking at the top of the vendors we evaluated in our 2020 Sales Performance Management Market Study," said Howard Dresner, founder and chief research officer at Dresner Advisory Services. "This 3rd edition of our study shows that sales performance management is seen as a core competitive enterprise component for organizations, and that the use of SPM software positively correlates to success with overall business intelligence initiatives."
The annual evaluation examines vendors’ Sales Performance Management (SPM) solutions against five key capabilities: Sales Planning, Sales Execution, Integration, Technology, and Deployment. Board, whose all-in-one decision-making platform combines Business Intelligence, planning, and predictive analytics capabilities and is used by more than 3,000 organizations worldwide to drive digital transformation of critical processes, achieved the highest total score in the study.
As the planning, monitoring, and forecasting of sales activities becomes increasingly complex, particularly as organizations look to take a tailored approach to each of their prospects, many enterprises are turning to SPM solutions to drive greater sales performance.
“I joined Board International because I was extremely impressed with the breadth and depth of the technology. Being recognized by Dresner Advisory Services as a #1 SPM platform confirms my initial thoughts. Having Board International’s BI and Predictive Analytics engine unified with all of the SPM components (Territory & Quota Management, Incentive Comp Management, Capacity Planning), our customers can not just plan but truly optimize their Sales Organization,” comments Jim Rich, General Manager Americas at Board.
Board International customers such as Mitsubishi Electric, part of the Mitsubishi Corporation, have achieved complete transparency of their sales performance. "We're now making business decisions quicker than ever before having selected Board as our sales performance management platform. We're serving more customers more products and using live data on quotes, sales and orders which has vastly improved sales process efficiencies," says Iain Blazey, General Manager IT Operations & Services at Mitsubishi Electric Europe. To learn more about Mitsubishi’s sales performance management success, see the case study .
For more information on the positioning and scoring methodology, see the full Wisdom of Crowds® Sales Performance Management Market Study 2020: https://www.board.com/en/learn/dresner-advisory-sales-performance-management-market-study-2020 .
About Board
Board is the #1 decision-making platform for organizations of any size. By unifying Business Intelligence, planning, and predictive analytics, the Board platform allows companies to produce a single, accurate, and complete view of business information, gain actionable insights, and achieve full control of performance across the entire organization. www.board.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20201102005735/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
The Estée Lauder Companies Appoints Madeleine Boyd as Senior Vice President, Global Brand Communications16.7.2026 22:22:00 CEST | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announced the appointment of Madeleine Boyd as Senior Vice President, Global Brand Communications, effective July 20, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716738393/en/ Photo by Esteban La Tessa As part of the company’s continued efforts to strengthen how its brands better connect with consumers, Ms. Boyd will establish and lead a newly integrated Global Brand Communications team. In this role, she will ensure the company’s diverse portfolio is anchored by a cohesive enterprise communications strategy, while accelerating bold, consumer-first storytelling that drives earned media, cultural relevance, and brand desirability. She will also strengthen creator engagement, helping the company’s brands gain attention where culture is being shaped. Ms. Boyd brings extensive experience spanning brand strategy, communications, consumer engagement, and cultural insight
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom